ANEMIA IN CHILDREN WITH CHRONIC KIDNEY DISEASE

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

Abstract Title *

ANEMIA IN CHILDREN WITH CHRONIC KIDNEY DISEASE

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Bassam Saeed bmsaeed2000@yahoo.com Farah Association for Child With Kidney Disease Pediatric Nephrology Damascus Syrian Arab Republic *

Co-author 2

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Anemia is a common and significant complication in children with chronic kidney disease (CKD), which increases in prevalence as the disease progresses.

Methods

Studies from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) report that up to 60% of children with CKD stage G2 and over 80% of those with CKD G5 are affected by anemia.

Results

This condition contributes to a range of clinical manifestations, including fatigue, pallor, and cognitive impairment and increases the need for blood transfusions and hospitalizations, thereby increasing morbidity and mortality. The etiology of anemia in CKD is multifactorial, involving erythropoietin (EPO) deficiency, iron deficiency, inflammation, blood loss, and the effects of medications. The Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) have issued guidelines for anemia management, which emphasize the need for individualized treatment strategies, such as erythropoiesis‑stimulating agents (ESAs) and iron supplementation. However, challenges remain regarding optimal hemoglobin targets, and ongoing research is needed to balance the benefits of ESAs with potential cardiovascular risks.

Conclusion

This review highlights the complexities of anemia in pediatric CKD, the role of key factors such as erythropoietin and iron in red blood cell maturation, and the importance of a tailored approach to treatment to improve patient outcomes.

Kewords